Summary
GlobalData, the industry analysis specialist, has released a new report, "Hepatitis C (HCV)-Pipeline Assessment and Market Forecasts to 2016". The report is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global hepatitis C sector. GlobalData's analysis suggests that the global HCV market was worth $4.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.8% for the next seven years to reach $8.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. GlobalData found that the global HCV market is becoming more competitive. When seen alongside the currently marketed products and the expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in the HCV is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects.

Table of Contents
1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 HCV: Market Characterization 5
2.1 Overview 5
2.2 HCV Market Size 5
2.3 HCV Market Forecast and Compound Annual Growth Rate 6
2.4 Drivers and Barriers for HCV Market 7
2.4.1 Drivers 7
2.4.2 Restraints 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 HCV Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.2.1 PegIntron (Peginterferon alfa-2b) in combination with Rebetol (Ribavirin) 11
3.2.2 Pegasys (peginterferon alfa-2a) in combination with Copegus (Ribavirin) 13
3.2.3 Infergen (Interferon alfacon-1) 15
3.2.4 Intron A (Interferon alfa 2b) in combination with Rebetol (Ribavirin) 16
3.3 Key Takeaway 18
4 HCV Market: Pipeline Assessment 19
4.1 Overview 19
4.2 Strategic Pipeline Assessment 19
4.2.1 Technology Trends Analytical Framework 19
4.3 HCV-Promising Drugs under Clinical Development 21
4.4 Drugs under Clinical Development 21
4.4.1 Boceprevir (SCH 503034) 21
4.4.2 Zalbin (albinterferon alfa-2b) 22
4.4.3 Telaprevir (VX 905) 24
4.4.4 RG 7128 26
4.5 HCV Market-Clinical Pipeline by Mechanism of Action 28
4.6 HCV Pipeline-Pipeline by Clinical Phases of Development 29
4.6.1 HCV Market-Phase III Clinical Pipeline 29
4.6.2 HCV Market-Phase II Clinical Pipeline 30
4.6.3 HCV Market-Phase I Clinical Pipeline 32
4.6.4 HCV Market-Preclinical Pipeline 34
4.6.5 HCV Market-Discovery 35
4.7 Discontinued/Suspended Drugs for HCV 36
4.8 Key Takeaway 37
5 HCV Market: Implications for Future Market Competition 38
6 HCV Market: Future Players in the HCV Market 39
6.1 Introduction 39
6.1.1 Merck & Co 39
6.1.2 F. Hoffmann-La Roche and Pharmasset 42
6.1.3 Human Genome Sciences and Novartis 45
6.1.4 Vertex Pharmaceuticals and Tibotec Pharmaceuticals 49
7 HCV Market: Appendix 54
7.1 Definitions 54
7.2 Abbreviations 54
7.3 Research Methodology 55
7.3.1 Coverage 56
7.3.2 Secondary Research 56
7.3.3 Forecasting 56
7.3.4 Primary Research 59
7.3.5 Expert Panels 59
7.4 Contact Us 59
7.5 Disclaimer 59
7.6 Sources 60

List of Tables
1.1 List of Tables
Table 1: Global HCV Market, Revenues ($m), 2001-2009 6
Table 2: Global HCV Market, Revenues ($m), 2009-2016 7
Table 3: Major Marketed Products in the HCV Market, 2010 17
Table 4: HCV-Most Promising Drugs Under Clinical Development, 2010 21
Table 5: Final Prove 3 SVR Results for Telaprevir, HCV 25
Table 6: Study Design for Phase II b study for RG7128, HCV 27
Table 7: HCV Market-Phase III Clinical Pipeline, 2010 29
Table 8: HCV Market-Phase II Clinical Pipeline, 2010 30
Table 9: HCV Market-Phase I Clinical Pipeline, 2010 32
Table 10: HCV Market-Pre Clinical Pipeline, 2010 34
Table 11: HCV Market-Discovery, 2010 35
Table 12: Discontinued/Suspended Drugs for HCV, 2010 36
Table 13: Merck & Co.-HCV marketed products, 2010 42
Table 14: Merck & Co.-HCV pipeline products, 2010 42
Table 15: Study Design for Phase II for RG7128, HCV 44
Table 16: F. Hoffmann-La Roche Ltd.-HCV marketed products, 2010 44
Table 17: F. Hoffmann-La Roche Ltd.-HCV pipeline product, 2010 44
Table 18: Pharmasset-HCV marketed products, 2010 45
Table 19: Human Genome Sciences-HCV pipeline products, 2010 48
Table 20: Novartis-HCV pipeline products, 2010 49
Table 21: Final Prove 3 SVR Results for telaprevir, HCV 51
Table 22: Vertex-HCV pipeline products, 2010 53
Table 23: Tibotec Pharmaceuticals-HCV pipeline products, 2010 53

List of Figures
1.2 List of Figures
Figure 1: HCV Market, Global, Revenues ($m), 2001-2009 6
Figure 2: HCV Market, Global, Revenues ($m), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the HCV Market, 2016 9
Figure 4: Strategic Competitive Assessment of Major Marketed Products for HCV, 2010 10
Figure 5: Technology Trends Analytic Framework of the HCV Pipeline, 2010 19
Figure 6: Technology Trends Analytic Framework of HCV,  Description, 2010 20
Figure 7: HCV Market-Clinical Pipeline by Mechanism of Action, 2010 28
Figure 8: HCV Pipeline by Phase of Clinical Development, 2010 29
Figure 9: Implications for Future Market Competition in the HCV Market, 2010 38
Figure 10: HCV Market-Clinical Pipeline by Company, 2010 39
Figure 11: GlobalData Methodology, 2010 55
Figure 12: GlobalData Market Forecasting Model, 2010 58